Nanocarriers can be engineered to exploit the unique characteristics of tumor microenvironments, such as leaky vasculature and acidic pH. By doing so, they preferentially accumulate in tumor tissues through the Enhanced Permeability and Retention (EPR) effect. Once at the tumor site, nanocarriers can release their payload in a controlled manner, maximizing therapeutic efficacy while minimizing systemic toxicity.
